Eloxatin
Chemoradiotherapy
Kangbuk Samsung HospitalPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 81/ 100
Competitive context
10 Active assets in the Chemoradiotherapy cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Carboplatin Shanghai Chest Hospital | Phase 3 | B |
CIS-DIAMMINEDICHLOROPLATINUM II Shanghai Chest Hospital | Phase 3 | B |
ETOPOSIDE Shanghai Chest Hospital | Phase 3 | B |
Capecitabine National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos | Phase 2/3 | B |
Ensartinib Shanghai Pulmonary Hospital, Shanghai, China | Phase 2 | CCC |
View all 11 →
Same molecule, other indications
Eloxatin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →